HLTX-001 / The Children’s Hospital of Philadelphia, Myrio Therap, Hula Therapeutics - LARVOL DELTA

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Stephan Grupp MD PhD | Not yet recruiting ➔ Recruiting

Enrollment open • Neuroblastoma • Oncology • Solid Tumor

U.S. Food & Drug Administration (FDA) Approves Investigational New Drug (IND) Application for Myrio's Lead Product (PHOX2B PC-CAR T) for the Treatment of Neuroblastoma (PRNewswire) - "On 7 May 2025, the FDA approved an IND application enabling Myrio's lead product (PHOX2B PC-CAR T) to enter human trials. Myrio, in collaboration the leading children's hospital in Philadelphia have co-developed a Chimeric Antigen Receptor (CAR-T) therapy for the treatment of neuroblastoma....The Phase 1 clinical trial entitled PHOX2B Peptide-Centric Chimeric Antigen Receptor Autologous T cells (PHOX2B PC-CAR T) for Relapsed Neuroblastoma will be conducted under the leadership of Prof. Maris and it is anticipated that the first patient will be enrolled mid-year 2025."

IND • Trial status • Neuroblastoma